Table 2.
Association of B2M expression with the clinicopathological features of patients with EOC
| Clinicopathological features | n | B2M expression | P value | |
|---|---|---|---|---|
| Positive (%) | Negative (%) | |||
| Age at diagnosis | ||||
| ≤45 | 8 | 6 (75.00) | 2 (25.00) | >0.999 |
| >45 | 24 | 19 (79.17) | 5 (20.83) | |
| Primary tumour size | ||||
| ≤2 cm | 4 | 4 (100.00) | 0 (0.00) | 0.552 |
| >2 cm | 28 | 21 (75.00) | 7 (25.00) | |
| Multifocal tumours | ||||
| Yes | 15 | 13 (86.67) | 2 (13.33) | 0.402 |
| No | 17 | 12 (70.59) | 5 (29.41) | |
| LN metastasis | ||||
| Yes | 4 | 3 (75.00) | 1 (25.00) | >0.999 |
| No | 28 | 22 (78.57) | 6 (21.43) | |
| FIGO stage | ||||
| I | 17 | 12 (70.59) | 5 (29.41) | 0.207 |
| II | 7 | 5 (71.43) | 2 (28.57) | |
| III | 8 | 8 (100.00) | 0 (0.00) | |
The expression of B2M proteins was detected by immunohistochemistry. For comparison of B2M expression associated with age, primary tumour size, multifocal, LN metastasis, and clinical stages, Fisher’s exact test was applied
EOC epithelial ovarian cancer; n number of cases; Positive positive expression; Negative negative expression; LN lymph node